Results 221 to 230 of about 169,479 (311)

Synergistic mechanisms of medullary cholinergic-serotonergic pathway interactions in regulating neuronal excitability and locomotor activities. [PDF]

Commun Biol
Cheng Y, Dai Y, Ge R, Zhang Q.
europepmc   +1 more source

Elevated Apolipoprotein E Expression in Hippocampal Microglia Drives Temporal Lobe Epilepsy Progression

Advanced Science, Volume 13, Issue 2, 9 January 2026.
In temporal lobe epilepsy, hippocampal APOE is markedly upregulated predominantly in microglia. APOE overexpression in microglia drives TLR4 and cGAS/STING‐dependent neuroinflammation, engages bidirectional crosstalk with neurons and astrocytes, increases neuronal excitability, and perturbs hippocampal lipid metabolism. These findings suggest that APOE‐
Jianwei Shi, Zesheng Li, Xin Sun, Yanfeng Yang, Yumin Luo, Ziang Song, Hengxin Dong, Lei Jin, Jing Xie, Yongzhi Shan, Guoguang Zhao   +10 more
wiley   +1 more source

Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort study

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Adults with Down syndrome (DS) display increased Alzheimer's disease (AD) risk. The cholinergic system declines early in the AD continuum and relates to cognitive and functional decline. We aimed to identify the timeline of cholinergic decline in relation to hippocampal atrophy within the AT(N) framework in DS.
Jason K. Russell, Zinayida Schlachetzki, Alexander C. Conley, Brian D. Boyd, Paul A. Newhouse, Paul S. Aisen, Michael S. Rafii, for the Alzheimer's Biomarker Consortium on Down Syndrome Study   +7 more
wiley   +1 more source

Nociceptor α7nAChR activation blunts neuronal HMGB1 release and attenuates inflammation and nociceptive behavior. [PDF]

Mol Med
Yang H, Morgan TS, Petruzzelli S, Hashimoto O, Hepler TD, Tynan A, Chaudhry S, Brines M, Andersson U, Chavan SS, Tracey KJ.   +10 more
europepmc   +1 more source

Six‐month follow‐up of ARIA‐H and iron deposition in real‐world lecanemab therapy for Alzheimer's disease: Evidence from a Chinese 7T MRI cohort

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION With the approval of lecanemab for treating Alzheimer's disease (AD), there is an urgent need to evaluate its safety and treatment effects on biomarkers in real‐world practice. METHODS Patients receiving lecanemab (n = 72) underwent routine 3T and 7T magnetic resonance imaging (MRI) for amyloid‐related imaging abnormality (ARIA ...
Weiwei Zhang, Haokun Liu, Cong Zhang, Yulai Li, Keying Fang, Yafang Zhou, Ling Weng, Liangjuan Fang, Yingying Luo, Han Xiao, Lin Zhou, Bin Jiao, Lu Shen   +12 more
wiley   +1 more source

Return to Spontaneous Circulation in a Patient With Cholinergic Syndrome at the Emergency Department of Buea Regional Hospital, Cameroon. [PDF]

Clin Case Rep
Nteungue BBK, Nyuydzefon B, Kouomogne BAN, Siysi VV.   +3 more
europepmc   +1 more source

Association between basal forebrain volume and age in the presenilin‐1 E280A autosomal dominant Alzheimer's disease kindred

Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION The basal forebrain (BF), a key cholinergic hub, undergoes atrophy in Alzheimer's disease (AD), contributing to cognitive decline. However, its age‐related differences and early vulnerability in autosomal dominant AD (ADAD) remain unclear.
Bing He, Paula Ospina Lopera, Alejandro Espinosa, Juan Camilo Becerra, Laura Osorio, Diana Alzate, Sergio Alvarez, Alice Grazia, Stefan J. Teipel, Vincent Malotaux, Catarina Tristão‐Pereira, Meredith C. Rowe, Averi Giudicessi, Yi Su, Yinghua Chen, Sonia Do Carmo, David Aguillón, A. Claudio Cuello, Yakeel T. Quiroz   +18 more
wiley   +1 more source